Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia

Next Previous
Search
Trial Profile

A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Janssen; Pharmacyclics

    • Most Recent Events

    • 07 Oct 2020 Development and validation of a four-factor prognostic model in Patients With Chronic Lymphocytic Leukemia treated with Ibrutinib; results published in the Journal of Clinical Oncology
    • 24 Mar 2020 Results from NCT01105247 and NCT01109069, evaluating Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia, published in the Clinical Cancer Research
    • 04 Dec 2018 Results of validation of prognostic model using pooled data of pooled analysis of four phase II and III studies (NCT01105247; NCT01578707; NCT01722487; NCT01744691), presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top